Loading stock data…
PRCT
$24.63+0.59 (+2.45%)
Market ClosedLast close May 1
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PROCEPT BioRobotics Corporation in the Healthcare sector is trading at $24.63. The stock is currently near its 52-week low of $19.35, remaining 26.1% below its 200-day moving average. Technical signals show neutral RSI of 55 and bullish MACD crossover, explaining why PRCT maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 55) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.63
Potential Upside
5%
Whystock Fair Value$25.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$30.44+23.6%
Range$20.00 – $37.00
Fundamentals
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic syste...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.42B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.00%
Volume
Today's trading volume
1.22M
Recent News
PROCEPT BioRobotics (PRCT)’s Growth Narrative Improves Following Aquablation Upgrade and HYDROS Launch
With a street-high upside potential of 109.4%, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ranks among the 10 best robotics stocks to buy under $30. PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has had a productive stretch heading into mid-2026, with two developments that together strengthen both the clinical and commercial case for Aquablation therapy. The first arrived on March 23, […]
Procept (PRCT) Q1 2026 Earnings Transcript
Larry Wood: Good afternoon, and thank you for joining us. While our commercial realignment initiatives modestly affected Q1 procedure growth, performance was largely in line with expectations. Regarding handpieces, we believe field inventory levels and customer purchasing behavior have normalized with handpieces sold representing approximately 95% of procedures in the first quarter.
PROCEPT BioRobotics Corporation Q1 2026 Earnings Call Summary
Moby summary of PROCEPT BioRobotics Corporation's Q1 2026 earnings call
PROCEPT BioRobotics Corp (PRCT) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Despite a notable revenue increase and improved gross margins, PROCEPT BioRobotics Corp (PRCT) faces challenges with increased net losses and operational disruptions.
PROCEPT BioRobotics Q1 Earnings Call Highlights
PROCEPT BioRobotics (NASDAQ:PRCT) reported first-quarter 2026 revenue of $83.1 million, up 20% year over year, as management pointed to early progress from organizational changes aimed at improving execution, pricing discipline, and profitability. Chief Executive Officer Larry Wood said the company